This difference in disease level was reflected in the spleen weight of mice from each treatment group such that untreated disease in the VEH-treated mice resulted in CLL-like marked splenomegaly that is significantly reduced with OPN5 treatment (Figure 3C). Here, OPN5 is linked to B-cell chronic lymphocytic leukemia.